Pyoderma Gangrenosum - 4 Studies Found
| RECRUITING |
: Spesolimab in Pyoderma Gangrenosum : Pyoderma Gangrenosum : 2024-11-21 : 900 mg of spesolimab intravenously (IV) administered at Weeks 0, 3, 6, 9, 12 and 15. |
| RECRUITING |
: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) : Pyoderma Gangrenosum : 2024-11-21 : Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks. |
| NOT_YET_RECRUITING |
: Deucravacitinib in PG : Pyoderma Gangrenosum : 2024-11-21 : 6 mg tablet |
| RECRUITING |
: Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum : Pyoderma Gangrenosum : 2024-11-21 : vilobelimab infusion |